Would a national pharmaceutical strategy be bad for the cardiovascular health of Canadians?
作者信息
Tu Jack V
出版信息
Can J Cardiol. 2007 Jul;23(9):719-20. doi: 10.1016/s0828-282x(07)70816-4.
Abstract
摘要
相似文献
1
Would a national pharmaceutical strategy be bad for the cardiovascular health of Canadians?
Can J Cardiol. 2007 Jul;23(9):719-20. doi: 10.1016/s0828-282x(07)70816-4.
2
Lessons for a national pharmaceuticals strategy in Canada from Australia and New Zealand.
Can J Cardiol. 2007 Jul;23(9):711-8. doi: 10.1016/s0828-282x(07)70815-2.
3
Rational use of medications: if Canada can't do it ..
CMAJ. 2009 Jul 7;181(1-2):15-6. doi: 10.1503/cmaj.090861.
4
Medication adherence: a call for action.
Am Heart J. 2011 Sep;162(3):412-24. doi: 10.1016/j.ahj.2011.06.007.
5
Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.
Lancet. 2016 Jan 2;387(10013):61-9. doi: 10.1016/S0140-6736(15)00469-9. Epub 2015 Oct 20.
6
[Pharmacoeconomics and cardiovascular disease].
Rev Clin Esp. 2004 Aug;204(8):391-2. doi: 10.1157/13064310.
7
Proceedings of a symposium: economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful health economic study for the pharmaceutical industry?
Am Heart J. 1999 May;137(5):S62-6. doi: 10.1016/s0002-8703(99)70431-x.
8
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluating the economic implications of cardiovascular therapeutics.
Am Heart J. 1999 May;137(5):S35-7. doi: 10.1016/s0002-8703(99)70425-4.
9
Orphan Drug Development in Cardiovascular Medicine.
Circ Cardiovasc Qual Outcomes. 2020 Jul;13(7):e006509. doi: 10.1161/CIRCOUTCOMES.119.006509. Epub 2020 Jun 19.
10
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Terminology I would like to see disappear.
Am Heart J. 1999 May;137(5):S51-2. doi: 10.1016/s0002-8703(99)70429-1.
本文引用的文献
1
The Canadian heart health strategy and action plan.
Can J Cardiol. 2009 Aug;25(8):451-2. doi: 10.1016/s0828-282x(09)70116-3.
2
Is ramipril really better than other angiotensin-converting enzyme inhibitors after acute myocardial infarction?
Am J Cardiol. 2006 Jul 1;98(1):6-9. doi: 10.1016/j.amjcard.2006.01.044. Epub 2006 Apr 27.
3
Heart health has an adverse future forecast in New Zealand: an alarm call to action across the continuum.
N Z Med J. 2006 Apr 21;119(1232):U1936.
4
Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Am Heart J. 2006 Feb;151(2):273-81. doi: 10.1016/j.ahj.2005.04.003.
5
Heart attacks and unstable angina (acute coronary syndromes) have doubled in New Zealand since 1989: how do we best manage the epidemic?
N Z Med J. 2005 Oct 7;118(1223):U1674.
6
Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.
CMAJ. 2005 Apr 26;172(9):1187-94. doi: 10.1503/cmaj.1041403.
7
Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.
Clin Pharmacol Ther. 2003 Oct;74(4):388-400. doi: 10.1016/S0009-9236(03)00227-3.
8
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
N Engl J Med. 2002 Mar 14;346(11):822-9. doi: 10.1056/NEJMsa003087.
9
Adverse events associated with prescription drug cost-sharing among poor and elderly persons.
JAMA. 2001;285(4):421-9. doi: 10.1001/jama.285.4.421.
10
Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia.
N Engl J Med. 1994 Sep 8;331(10):650-5. doi: 10.1056/NEJM199409083311006.
Zotero 插件